88 related articles for article (PubMed ID: 24447555)
1. [Effect of staining condition on HER2 immunohisto chemistry of breast cancer tissues].
Luo XL; Xu FP; Luo DL; Lin XT; Zhu XL; Xu J; Chen J; Zhang W; Liu YH
Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):760-3. PubMed ID: 24447555
[No Abstract] [Full Text] [Related]
2. Validation of a fully automated HER2 staining kit in breast cancer.
Moelans CB; Kibbelaar RE; van den Heuvel MC; Castigliego D; de Weger RA; van Diest PJ
Cell Oncol; 2010; 32(1-2):149-55. PubMed ID: 20203372
[TBL] [Abstract][Full Text] [Related]
3. Machine scoring of Her2/neu immunohistochemical stains.
Bishop JW; Marcelpoil R; Schmid J
Anal Quant Cytol Histol; 2002 Oct; 24(5):257-62. PubMed ID: 12408558
[TBL] [Abstract][Full Text] [Related]
4. Luminal B breast tumors are not HER2 positive.
Bhargava R; Dabbs DJ
Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
[No Abstract] [Full Text] [Related]
5. Immunohistochemical assays for HER2 overexpression.
Maia DM
J Clin Oncol; 1999 May; 17(5):1650. PubMed ID: 10334562
[No Abstract] [Full Text] [Related]
6. National HER2 proficiency test results using standardized quantitative controls: characterization of laboratory failures.
Vani K; Sompuram SR; Fitzgibbons P; Bogen SA
Arch Pathol Lab Med; 2008 Feb; 132(2):211-6. PubMed ID: 18251579
[TBL] [Abstract][Full Text] [Related]
7. HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma.
Horiguchi S; Hishima T; Hayashi Y; Shiozawa Y; Horiguchi K; Kuroi K; Toi M; Funata N; Eishi Y
J Med Dent Sci; 2010 Jun; 57(2):155-63. PubMed ID: 21073134
[TBL] [Abstract][Full Text] [Related]
8. Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTestTM in breast carcinoma by image analysis.
Hatanaka Y; Hashizume K; Kamihara Y; Itoh H; Tsuda H; Osamura RY; Tani Y
Pathol Int; 2001 Jan; 51(1):33-6. PubMed ID: 11148461
[TBL] [Abstract][Full Text] [Related]
9. Correspondence re: Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000;13:37-45.
Hugh J; Barley R; Dabbagh L
Mod Pathol; 2001 Mar; 14(3):263. PubMed ID: 11266538
[No Abstract] [Full Text] [Related]
10. [Quality challenge for immunohistochemistry: example of the ERBB-2 status in breast cancer. Group for Evaluation of Prognostic Factors in Immunohistochemistry in Breast Cancer (GEFPICS)].
Penault-Llorca F; Jacquemier J; Le Doussal V; Voigt JJ
Ann Pathol; 1999 Sep; 19(4):280-2. PubMed ID: 10544761
[No Abstract] [Full Text] [Related]
11. The quality of Her-2/Neu predictive immunohistochemistry: something FISHy?
Tubbs RR; Stoler MH
Mod Pathol; 2000 Jan; 13(1):1-3. PubMed ID: 10658903
[No Abstract] [Full Text] [Related]
12. [Her2-Neu expression in ductal adenocarcinomas of the breast gland: correlation with histopathological parameters and estrogen receptors' expression in Mexican patients].
Brück P; Vilches Cisneros N; Ramos López E; Barboza Quintana O; Ancer Rodríguez J; Flores Gutiérrez JP
Ginecol Obstet Mex; 2006 Oct; 74(10):516-22. PubMed ID: 21961357
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of HER-2/neu overexpression among Iranian women with breast cancer: true or false?
Saatee S; Afrakhteh M; Sadrolhefazi B
Breast J; 2006; 12(5):499-501. PubMed ID: 16958978
[No Abstract] [Full Text] [Related]
14. Prognostic factors and survival analysis of invasive ductal carcinoma of the breast in Bandung, Indonesia.
Hernowo BS; Yukawa M; Asaka K; Fujimori T; Maeda S; Mukawi TY
Kobe J Med Sci; 1995 Aug; 41(4):95-112. PubMed ID: 8904161
[No Abstract] [Full Text] [Related]
15. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
[TBL] [Abstract][Full Text] [Related]
16. Comparison of automated and manual determination of HER2 status in breast cancer for diagnostic use: a comparative methodological study using the Ventana BenchMark automated staining system and manual tests.
Bánkfalvi A; Boecker W; Reiner A
Int J Oncol; 2004 Oct; 25(4):929-35. PubMed ID: 15375542
[TBL] [Abstract][Full Text] [Related]
17. [Immunochemistry evaluation of HER2 status in infiltration breast cancer: technical protocol and interpretation guidelines].
Penault-Llorca F; Balaton A; Sabourin JC; Le Doussal V;
Ann Pathol; 2002 Apr; 22(2):150-7. PubMed ID: 12124503
[TBL] [Abstract][Full Text] [Related]
18. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
[TBL] [Abstract][Full Text] [Related]
19. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
Jimenez RE; Wallis T; Tabasczka P; Visscher DW
Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
[TBL] [Abstract][Full Text] [Related]
20. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.
Sanlioglu AD; Korcum AF; Pestereli E; Erdogan G; Karaveli S; Savas B; Griffith TS; Sanlioglu S
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):716-23. PubMed ID: 17512128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
